ClinicalTrials.Veeva

Menu
T

The Children's Hospital at Westmead | Cancer Centre for Children

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cyclophosphamide
Etoposide
Carboplatin
Vincristine Sulfate
Cisplatin
Doxorubicin Hydrochloride
Temozolomide
Vincristine
Irinotecan Hydrochloride
Thiotepa

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

30 of 133 total trials
Locations recently updated

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (ENVISION)

The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD...

Enrolling
Duchenne Muscular Dystrophy
Genetic: placebo
Genetic: delandistrogene moxeparvovec

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for redu...

Invitation-only
Peanut Allergy
Peanut-Induced Anaphylaxis
Biological: Placebo
Biological: PVX-108

This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that...

Active, not recruiting
Desmoid Fibromatosis
Unresectable Desmoid Fibromatosis
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment

The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to...

Active, not recruiting
Relapsed Solid Tumor
Refractory Solid Tumor
Drug: GM-CSF
Drug: Abemaciclib

This Phase IIb study is a two part, multicenter study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ATL1102 in non-ambul...

Active, not recruiting
Duchenne Muscular Dystrophy
Drug: Placebo
Drug: ATL1102 50mg

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatiti...

Active, not recruiting
Atopic Dermatitis
Drug: Topical corticosteroid
Drug: Baricitinib

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This st...

Enrolling
Juvenile Idiopathic Arthritis
Drug: Baricitinib

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of th...

Enrolling
Crohn's Disease
Drug: Mirikizumab

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET...

Enrolling
Infantile Fibrosarcoma
Soft Tissue Sarcoma
Drug: LOXO-292

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or me...

Enrolling
Locally Advanced Solid Tumors
Primary CNS Tumors
Drug: Oral repotrectinib (TPX-0005)
Status recently updated

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition...

Not yet enrolling
Enrolling
Weight Gain
Obesity
Drug: Tirzepatide
Drug: Placebo

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone nor...

Enrolling
Fibrodysplasia Ossificans Progressiva
Drug: IPN60130
Drug: Placebo

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Enrolling
Atopic Dermatitis
Eczema
Drug: Lebrikizumab
Drug: Placebo

FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, a...

Enrolling
Low-grade Glioma
Advanced Solid Tumor
Drug: DAY101

A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.

Enrolling
Respiratory Syncytial Virus (RSV)
Drug: EDP-938
Drug: Placebo

This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at...

Active, not recruiting
Severe Hemophilia A
Drug: Emicizumab
Locations recently updated

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diab...

Active, not recruiting
Type2 Diabetes
Glucose Metabolism Disorders
Drug: Placebo
Drug: Tirzepatide Dose 2

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria,...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)
Drug: Placebo

This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-10...

Active, not recruiting
Atopic Dermatitis
Type 1 Hypersensitivity
Biological: Placebo
Biological: STMC-103H

Trial sponsors

C
National Cancer Institute (NCI) logo
Lilly logo
Vertex Pharmaceuticals logo
BioMarin Pharmaceutical logo
Pfizer logo
PTC Therapeutics logo
T
Roche logo
Shire logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems